Allianz Asset Management
BBIO icon

Allianz Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Allianz Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$728K Hold
9,800
– – ﹤0.01% 1896
2026
Q1 		$728K Sell
9,800
-15,300
-61% -$1.11M ﹤0.01% 1780
2025
Q4 		$1.92M Buy
25,100
+1,600
+7% +$105K ﹤0.01% 1557
2025
Q3 		$1.22M Buy
23,500
+11,200
+91% +$546K ﹤0.01% 1668
2025
Q2 		$531K Buy
12,300
+4,500
+58% +$164K ﹤0.01% 1821
2025
Q1 		$270K Buy
+7,800
New +$263K ﹤0.01% 2065
2023
Q2 		– Sell
-21,100
Closed -$350K – 2154
2023
Q1 		$350K Buy
+21,100
New +$246K ﹤0.01% 1963
2022
Q1 		– Sell
-33,228
Closed -$554K – 2412
2021
Q4 		$554K Sell
33,228
-8,130
-20% -$344K ﹤0.01% 2157
2021
Q3 		$1.94M Sell
41,358
-2,900
-7% -$155K ﹤0.01% 1665
2021
Q2 		$2.7M Sell
44,258
-13,860
-24% -$792K ﹤0.01% 1368
2021
Q1 		$3.58M Buy
58,118
+29,658
+104% +$1.94M ﹤0.01% 1190
2020
Q4 		$2.02M Hold
28,460
– – ﹤0.01% 1310
2020
Q3 		$1.07M Sell
28,460
-2,550
-8% -$80.2K ﹤0.01% 1416
2020
Q2 		$1.01M Sell
31,010
-24,749
-44% -$754K ﹤0.01% 1824
2020
Q1 		$1.62M Sell
55,759
-25,337
-31% -$786K ﹤0.01% 1601
2019
Q4 		$2.84M Buy
+81,096
New +$2.25M ﹤0.01% 1728

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Allianz Asset Management's BBIO Position: Q2 2026 in Review

Allianz Asset Management held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 9,800 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #1896.

Allianz Asset Management first reported a position in BBIO in Q4 2019 and has held it in 16 quarters since. The position peaked at $3.58M in Q1 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Allianz Asset Management held 9,800 shares of BridgeBio Pharma worth $728K as of Q2 2026.
  • Allianz Asset Management left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1896 holding.
  • Allianz Asset Management first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 16 quarters since.
  • Allianz Asset Management's BridgeBio Pharma position peaked at $3.58M in Q1 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.